Platform Validation Cases

5 Tier-III Hospitals · 5 Indications · 5 Formulation Types — Full-stack validation of the ΞSyn Labs delivery platform

5

Hospital Partners

5

Indications Validated

3

National Grants

Case 01 · Dermal Delivery

CoQ10 Transdermal Nanovesicles

Nanovesicle + hyaluronic acid hydrogel synergistic delivery system. Overcomes the industry challenges of poor CoQ10 transdermal penetration and short local retention, achieving follicle-targeted delivery with sustained local residence.

TechnologyNanovesicles + Hydrogel

Partner HospitalThe Sixth Affiliated Hospital, Sun Yat-sen University

FundingNational Natural Science Foundation of China

16.6×

Local Bioavailability Improvement

>5×

Transdermal Efficiency Improvement

>85%

Encapsulation Efficiency · Stable PDI

4 wks

Continuous Human Use Validation

Mechanism

Liposome
Encapsulation→ Nanovesicle
Stratum Corneum→ HA Hydrogel
Local Retention→ Follicle-Targeted
Sustained Release

Dual-component synergy: Liposomes/nanovesicles handle encapsulation and transdermal penetration; bio-based materials (hyaluronic acid) provide local retention, moisturization, and sustained release. Full-chain control from "stable encapsulation" to "transdermal retention."

Experimental Validation

Human Validation: 4-Week Continuous UseVisible improvement in thinning area coverage, significant user-perceived effect.

Comprehensive Hydrogel CharacterizationTissue adhesion, biocompatibility, antioxidant (DPPH ~55%, superoxide ~95%), anti-inflammatory (IL-6 reduction), transdermal retention.

38.9 μg/g

Optimal skin retention
16.6× vs control

55%

DPPH radical scavenging
Sustained at 12h

~95%

Superoxide anion clearance
Near-complete at 12h

Case 02 · Wound Repair

Dual-Domain Living Particle Gel

S. elongatus living microalgae + PRP regenerative signals — intra-particle oxygen supply, inter-particle growth factor delivery, synergistically resolving the dual challenges of persistent hypoxia and burst-release in diabetic chronic wounds.

TechnologyParticle Gel / Living Material

Partner HospitalZhongshan Hospital, Fudan University

FundingNational Key R&D Program — Synthetic Biology

~90%

Day 12 Wound Closure

+20%

Fibroblast Migration Increase

~2×

Vessel Area Ratio Increase

85%

Wound Closure Rate
vs DM Control 58%

Mechanism

Intra-particle
S. elongatus→ Light-Activated
Sustained O₂→ Inter-particle
PRP GF Release→ Angiogenesis
Tissue Regeneration

Dual-domain design: Photosynthetic microalgae (S. elongatus) encapsulated within microparticles provide light-driven, sustained O₂ production to reverse the hypoxic microenvironment. PRP loaded in inter-particle spaces releases PDGF-BB, VEGF, TGF-β1, and multiple other growth factors, synergistically promoting vascularization and wound closure.

Experimental Validation

GHLMs Dual-Domain ArchitectureIntra-particle O₂ module (S. elongatus) + inter-particle regenerative signal module (PRP → PDGF-BB / VEGF / TGF-β1).

Endothelial Cell Functional ValidationMigration, scratch wound healing, and tube formation assays — GHLMs significantly outperformed all controls (Control / GHs / HLMs).

In Vivo Efficacy

STZ-Induced Diabetic Mouse Wound ModelDay 0→12 healing progression. GHLMs group achieved near-complete wound closure by Day 12, while DM Control retained a large unhealed wound area.

Wound Closure QuantificationDM GHLMs ~85% vs DM Control ~58%, statistically significant (*p<0.05).

Case 03 · Bone Repair

Injectable Exosome Microspheres

HMP microspheres loaded with miR-29a exosomes — microfluidic fabrication of uniform microspheres, RGD-targeted bone lesion localization, 28-day sustained release, synergistically driving osteogenesis and angiogenesis.

TechnologyExosome + HMP Microspheres

Partner HospitalNanjing First Hospital

FundingNational Natural Science Foundation of China

14.3×

Osteogenic Gene Upregulation

2.3×

Angiogenic Protein Increase

28 days

Sustained Release Period

−82%

HDAC4 Suppression

Mechanism

Microfluidic
Droplet Fabrication→ HMP Microspheres
RGD Targeting→ Injection into
Bone Lesion→ miR-29a
Osteo + Angio

Dual-responsive release + bone-vascular synergy: RGD peptides on HMP microsphere surfaces target BMSCs and HUVECs. Microspheres respond to pathological microenvironments (hyaluronidase / ROS) for sustained exosome release. miR-29a-3p enters cells → inhibits HDAC4 → upregulates Runx2 → drives osteogenic differentiation (ALP / COL1 / OCN / BMP2) and angiogenesis (VEGF).

Experimental Validation

$Rat fracture repair$

Rat Fracture Model Repair AssessmentX-ray + micro-CT imaging follow-up (1/3/5 weeks). HMP@Agomir-29a-Exo group showed near-complete fracture healing at 5 weeks, with BMD, BV/TV, and Tb.Th significantly superior to all controls.

HMP-Exo 28-Day Cumulative ReleaseHyaluronidase group: ~82% release at 28 days; H₂O₂ group: ~95% at 20 days. Near-zero leakage in normal PBS — dual-responsive to pathological microenvironments.

+26%

5-week BMD increase
vs HMP@Exo

+12%

5-week BV/TV increase
New bone volume fraction

+13%

6h vessel length increase
Vessel node increase

Case 04 · Colitis Treatment

NO-Responsive Probiotic Microcapsules

γ-PGA hydrogel microcapsules encapsulating Lactobacillus acidophilus — gastric acid-resistant, intestinal NO-triggered release, simultaneously restoring the intestinal barrier, modulating the microbiota, and reducing inflammation.

TechnologyMicrocapsule / Microgel

Partner HospitalThe First Affiliated Hospital of USTC

FundingNational Key R&D Program — Synthetic Biology

89.67%

SGF 3h Survival
Free bacteria: 0%

93.67%

SIF 3h Survival
Free bacteria: 61.60%

67.86%

NO-Triggered 12h Release
No NO: only 4.64%

6.0×10⁸

cells/mL
High-Density Encapsulation

Mechanism

Microfluidic
Encapsulation→ γ-PGA Shell
Gastric Resistance→ Intestinal NO
Triggered Release→ Microbiota Modulation
Barrier Repair

Oral→Stomach→Intestine three-stage delivery: Uniform γ-PGA microcapsules fabricated by microfluidics. The acid-resistant shell protects probiotics through the stomach. Upon reaching inflamed intestinal sites, the capsules respond to locally elevated NO for precise release. Released probiotics colonize the intestinal epithelium, restoring barrier function + optimizing microbiota + reducing inflammatory cytokines.

Experimental Validation

Encapsulation Performance ValidationSGF/SIF survival rates, live/dead fluorescence staining, SEM morphology — microcapsules maintained structural integrity, survival significantly exceeding free bacteria.

Barrier Repair + Microbiota ModulationTEER recovery to ~85%, cell viability ~90%. Phylum/genus-level analysis: NRPM group microbiota most closely resembled the normal control.

In Vivo Efficacy

Disease Activity Index (DAI)NRPM group peak DAI only ~1.3 (vs Ctrl/PBS ~3.3), declining to 0.8 by Day 7 — disease progression significantly suppressed.

Colon Length RestorationNRPM group ~6.9cm vs PBS ~5.2cm (**p<0.01), colon shortening significantly alleviated.

Case 05 · Cardiac Targeting

Cardiac-Targeted nano-MaR1

PEGylated liposomes encapsulating Maresin 1 — enriched in ischemic myocardium after IV administration, alleviating post-MI microvascular obstruction (MVO) and reducing infarct size.

TechnologyTargeted Liposomes

Partner HospitalNanjing Drum Tower Hospital

StatusIn Development

PEG

Long-Circulating Liposomes
Extended half-life

MaR1

Pro-Resolving Mediator
Myocardial targeting

MVO

Microvascular Obstruction
Core post-MI challenge

IV

Intravenous Administration
Systemic delivery

Mechanism

PEG Liposome
Encapsulating MaR1→ IV Injection
Long Circulation→ Ischemic Myocardium
Passive Targeting→ MVO Alleviation
Infarct Reduction

Clinical challenge: MaR1 is inherently unstable and rapidly degraded, making precise myocardial lesion targeting difficult. Post-MI microvascular obstruction (MVO) currently lacks effective interventions. PEGylated liposomal delivery enhances MaR1 stability, prolongs circulation time, improves lesion targeting efficiency, and significantly reduces infarct size and inflammatory infiltration.

Delivery Challenges
· MaR1 chemical instability
· Extremely short free-drug half-life
· Poor myocardial lesion enrichment
· No effective MVO intervention

Liposomal Solution
· PEGylation extends circulation
· Nano-size enables passive ischemic targeting
· Protects MaR1 from degradation
· Reduces infarct size + alleviates MVO

ΞSyn Labs · Platform Summary

Platform Capability Matrix

Product	Formulation	Route	Partner Hospital	Key Metric
CoQ10 Transdermal	Nanovesicles + Hydrogel	Transdermal · Follicle	SYSU 6th Hospital	16.6× Bioavailability
Dual-Domain Gel	Living Microalgae + PRP	Local Injection/Topical	Zhongshan Hosp. Fudan	Day 12 Closure ~90%
Exosome Microspheres	HMP + miR-29a	In Situ Injection	Nanjing First Hospital	Osteogenic ↑14.3×
NO-Responsive MC	γ-PGA Microcapsules	Oral · NO-Triggered	USTC 1st Hospital	Gastric Survival 89.67%
nano-MaR1	PEG Liposomes	IV · Systemic	Nanjing Drum Tower	MVO Alleviation

Encode · Form Factor

Nanovesicles · Liposomes · Microspheres · Microcapsules · Particle Gels — 5 formulation types covering transdermal/oral/injectable/topical all administration routes.

Screen · Targeting Validation

Follicle · Bone Lesion · Colitis Site · Ischemic Myocardium — 4 targeting strategies validated from cell to animal to human.

Manufacture · Translation

Microfluidic scale-up · Continuous flow · 5 hospital validations · 3 national grants — a replicable path from bench to bedside.